NEVVI Medicare utilization intelligence
or

← back

Provider profile

UYEKI, JAMES M.D.

Medical Oncology · NPI 1124187927 · AUSTIN, TX

1
Groups
88
Codes · 2024
267,970
Disclosed services

UYEKI, JAMES is a Medical Oncology in AUSTIN, TX, a member of 1 medical group, who billed 88 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

267,970
disclosed services
88
codes billed to Medicare Part B
Prior year · CY2023 408,789 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9299 Injection, nivolumab, 1 mg
J1756 Injection, iron sucrose, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0897 Injection, denosumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
83615 Lactate dehydrogenase (enzyme) level
J1437 Injection, ferric derisomaltose, 10 mg
83735 Magnesium level
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1626 Injection, granisetron hydrochloride, 100 mcg
J2469 Injection, palonosetron hcl, 25 mcg
J3480 Injection, potassium chloride, per 2 meq
83540 Iron level
83550 Iron binding capacity
82728 Ferritin (blood protein) level
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82784 Gammaglobulin (immune system protein) measurement
J1750 Injection, iron dextran, 50 mg
J7030 Infusion, normal saline solution , 1000 cc
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J3475 Injection, magnesium sulfate, per 500 mg
96372 Injection of drug or substance under skin or into muscle
J2506 Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
83521 Measurement of immunoglobulin light chains
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J9190 Injection, fluorouracil, 500 mg
96360 Infusion into a vein for hydration, 31-60 minutes
82378 Carcinoembryonic antigen (cea) protein level
J1200 Injection, diphenhydramine hcl, up to 50 mg
96361 Infusion into a vein for hydration, each additional hour
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
85055 Reticulated (young) platelet measurement
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
84443 Blood test, thyroid stimulating hormone (tsh)
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
84550 Uric acid level, blood
J3490 Unclassified drugs
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96374 Injection of drug or substance into vein
84153 Psa (prostate specific antigen) measurement, total
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
85045 Red blood count, automated test
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96377 Application of on-body injector for under skin injection
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
84403 Testosterone (hormone) level, total
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96411 Administration of additional new drug or substance into vein using push technique
99195 Drawing of blood for a medical problem
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
81001 Manual urinalysis test with examination using microscope, automated
82105 Alpha-fetoprotein (afp) level, serum
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
83690 Lipase (fat enzyme) level
82232 Beta-2 microglobulin (protein) level
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
93306 Ultrasound of heart with color-depicted blood flow, rate, direction and valve function
84439 Thyroxine (thyroid chemical), free
71260 Ct scan of chest with contrast
74177 Ct scan of abdomen and pelvis with contrast

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.